Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. - Wikidata - wikimedia - TriplyDB

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.

http://www.wikidata.org/entity/Q37982112

about

Saxagliptin overview: special focus on safety and adverse effects Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Efficacy and safety of Jentadueto® (linagliptin plus metformin).Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.

P2860

Q28278863-79493125-F1CF-4928-8201-D8608ECCE2BC Q38078436-09079A92-39D0-40D5-9D1F-7B5A6695ABED Q38082848-F7FC53F8-91AD-4A1A-8D04-C5535D437CB4 Q38086611-41DFE99A-0124-45CC-A52B-D75A1F835127 Q38261573-7375E063-6B04-430A-83B7-D4CB1A5F9198 Q38734181-4A23655F-B378-418F-A5AC-2D9168805110 Q38856808-3700321A-AB5D-4514-A9BD-73DB7882CFA4 Q47687852-149EBEFC-ABCD-4EDD-9531-7F6F5E601A32

P2860

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.

http://www.wikidata.org/entity/Q37982112

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Saxagliptin plus metformin co ...... diabetes and renal impairment.

@en

Saxagliptin plus metformin co ...... diabetes and renal impairment.

@nl

type

label

Saxagliptin plus metformin co ...... diabetes and renal impairment.

@en

Saxagliptin plus metformin co ...... diabetes and renal impairment.

@nl

prefLabel

Saxagliptin plus metformin co ...... diabetes and renal impairment.

@en

Saxagliptin plus metformin co ...... diabetes and renal impairment.

@nl

P1433

Q37982112-6AF35617-B35E-48D4-AF8B-9E393402DE58

P1476

Q37982112-8F1A9F77-E7D9-48D5-9BFA-8F8ECCD94D01

P2093

Q37982112-22AC93E8-07B7-45E9-A24F-BD0F8A39E292

P2860

Q37982112-002DBCF0-A392-4F5B-9096-BF9DC6F2F598

Q37982112-00F2AA63-1A88-477D-8696-2C005EF1FDED

Q37982112-01F8EF94-F4A8-428D-A2FE-D94E20D44DAA

Q37982112-04CD694B-0C1A-4BC0-A8FB-59DE86E494D6

Q37982112-1754A9C3-936F-4277-8DDB-97E1A5F20BF7

Q37982112-19C3A8FC-6D96-4E45-BBE8-031EB6749434

Q37982112-20DF05D3-B3A7-45AA-9272-55FE4CD6142E

Q37982112-21422D60-30E7-4A41-901C-7E8836488B85

Q37982112-2BB9720D-2443-4216-A2A6-B8DB8464F692

Q37982112-2C7D5F17-D046-45D2-A315-0124CCA4B5A4

P304

Q37982112-E1B6483B-63DC-479A-8A8C-7008244BCBE8

P31

Q37982112-D100C1FC-90D6-4D22-A2B2-08EC7752E06F

P356

Q37982112-BE23BDC5-2B0A-4D94-8EC8-CCFDCF5F5A15

P407

Q37982112-0AF2E68A-2972-4F58-9CE3-54408C6A5355

P433

Q37982112-83497A3C-A47D-4ED1-B8E2-FA742FACF034

P478

Q37982112-22C7913A-903A-41A7-B27A-10B95F296927

P577

Q37982112-51DBE579-1785-4774-BE1D-BBFE8544667C

P698

Q37982112-171FE68D-7DA5-4340-A0FA-9E6D8CE8885B

P921

Q37982112-70266755-7263-42A9-B66F-EE30B58F202D

Q37982112-BAFBB0E4-ECC0-4027-8DD4-3A76BDAF236C

Q37982112-C1F095E1-15FB-4A19-B546-38A480FC1369

P356

17425255.2012.658771

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Saxagliptin plus metformin co ...... diabetes and renal impairment.

@en

P2093

André J Scheen

http://www.w3.org/2001/XMLSchema#string

P2860

Use of metformin in the setting of mild-to-moderate renal insufficiency

Clinical Pharmacokinetics of Metformin

Fixed-dose single tablet antidiabetic combinations

Reduction of metformin renal tubular secretion by cimetidine in man

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

Current understanding of the pharmacogenomics of metformin.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

10-year follow-up of intensive glucose control in type 2 diabetes

Lactic acidosis induced by metformin: incidence, management and prevention.

P304

383-394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2012.658771

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22313172

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes